FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560639583> ?p ?o ?g. }

• W2560639583 endingPage "3225" @default.
• W2560639583 startingPage "3206" @default.
• W2560639583 abstract "// Qing Wen 1 , Philip D. Dunne 1 , Paul G. O’Reilly 1 , Gerald Li 1 , Anthony J. Bjourson 2 , Darragh G. McArt 1 , Peter W. Hamilton 1, * , Shu-Dong Zhang 1, 2, * 1 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK 2 Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, C-TRIC, Londonderry, UK * Joint Senior Author Correspondence to: Qing Wen, email: qwen02@qub.ac.uk Peter W. Hamilton, email: P.Hamilton@qub.ac.uk Keywords: connectivity mapping, differentially expressed genes, colorectal cancer, KRAS mutation, FDA approved drugs Received: May 15, 2016      Accepted: November 30, 2016      Published: December 10, 2016 ABSTRACT Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) CRCs, there still remains no effective therapeutic course for advanced KRAS mutant (KRAS-MT) CRC patients. In this study, we employed a novel and comprehensive approach of gene expression connectivity mapping (GECM) to identify candidate compounds to target KRAS-MT tumors. We first created a combined KRAS-MT gene signature with 248 ranked significant genes using 677 CRC clinical samples. A series of 248 sub-signatures was then created containing an increasing number of the top ranked genes. As an input to GECM analysis, each sub-signature was translated into a statistically significant therapeutic drugs list, which was finally combined to obtain a single list of significant drugs. We identify four antihypertensive angiotensin II receptor blockers (ARBs) within the top 30 significant drugs indicating that these drugs have a mechanism of action that can alter the KRAS-MT CRC oncogenic signaling. A hypergeometric test ( p-value = 6.57 × 10 −6 ) confirmed that ARBs are significantly enriched in our results. These findings support the hypothesis that ARB antihypertensive drugs may directly block KRAS signaling resulting in improvement in patient outcome or, through a reversion to a KRAS wild-type phenotype, improve the response to anti-EGFR treatment. Antihypertensive angiotensin II receptor blockers are therefore worth further investigation as potential therapeutic candidates in this difficult category of advanced colorectal cancers." @default.
• W2560639583 created "2016-12-16" @default.
• W2560639583 creator A5008176647 @default.
• W2560639583 creator A5023247048 @default.
• W2560639583 creator A5026962542 @default.
• W2560639583 creator A5039482198 @default.
• W2560639583 creator A5044148216 @default.
• W2560639583 creator A5055241025 @default.
• W2560639583 creator A5068930694 @default.
• W2560639583 creator A5078758349 @default.
• W2560639583 date "2016-12-10" @default.
• W2560639583 modified "2023-09-30" @default.
• W2560639583 title "KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies" @default.
• W2560639583 cites W1806432442 @default.
• W2560639583 cites W1904099440 @default.
• W2560639583 cites W1969353479 @default.
• W2560639583 cites W1969851044 @default.
• W2560639583 cites W1974071557 @default.
• W2560639583 cites W1974439234 @default.
• W2560639583 cites W1982929992 @default.
• W2560639583 cites W1983040612 @default.
• W2560639583 cites W1988729646 @default.
• W2560639583 cites W1989909503 @default.
• W2560639583 cites W1990065094 @default.
• W2560639583 cites W1992407562 @default.
• W2560639583 cites W1995919174 @default.
• W2560639583 cites W1996906699 @default.
• W2560639583 cites W2000896073 @default.
• W2560639583 cites W2002783201 @default.
• W2560639583 cites W2006485696 @default.
• W2560639583 cites W2007113041 @default.
• W2560639583 cites W2008744145 @default.
• W2560639583 cites W2010161400 @default.
• W2560639583 cites W2021968441 @default.
• W2560639583 cites W2029952579 @default.
• W2560639583 cites W2029980980 @default.
• W2560639583 cites W2030531674 @default.
• W2560639583 cites W2033042382 @default.
• W2560639583 cites W2034269086 @default.
• W2560639583 cites W2041183742 @default.
• W2560639583 cites W2041724468 @default.
• W2560639583 cites W2041935553 @default.
• W2560639583 cites W2043282329 @default.
• W2560639583 cites W2043398720 @default.
• W2560639583 cites W2044773944 @default.
• W2560639583 cites W2047884280 @default.
• W2560639583 cites W2055270214 @default.
• W2560639583 cites W2062941476 @default.
• W2560639583 cites W2063432807 @default.
• W2560639583 cites W2064974844 @default.
• W2560639583 cites W2075340577 @default.
• W2560639583 cites W2076604395 @default.
• W2560639583 cites W2091321756 @default.
• W2560639583 cites W2091334045 @default.
• W2560639583 cites W2096235123 @default.
• W2560639583 cites W2098360608 @default.
• W2560639583 cites W2108068107 @default.
• W2560639583 cites W2110820285 @default.
• W2560639583 cites W2111502453 @default.
• W2560639583 cites W2112078762 @default.
• W2560639583 cites W2117692326 @default.
• W2560639583 cites W2119562899 @default.
• W2560639583 cites W2120341265 @default.
• W2560639583 cites W2121604817 @default.
• W2560639583 cites W2124123867 @default.
• W2560639583 cites W2125789330 @default.
• W2560639583 cites W2128211963 @default.
• W2560639583 cites W2129395051 @default.
• W2560639583 cites W2142080475 @default.
• W2560639583 cites W2144330713 @default.
• W2560639583 cites W2151096273 @default.
• W2560639583 cites W2152883907 @default.
• W2560639583 cites W2154941270 @default.
• W2560639583 cites W2157114765 @default.
• W2560639583 cites W2158289038 @default.
• W2560639583 cites W2159482845 @default.
• W2560639583 cites W2160843698 @default.
• W2560639583 cites W2175970000 @default.
• W2560639583 cites W2200675409 @default.
• W2560639583 cites W2214619601 @default.
• W2560639583 cites W2274051839 @default.
• W2560639583 cites W2287891688 @default.
• W2560639583 cites W2345869233 @default.
• W2560639583 cites W2411481351 @default.
• W2560639583 cites W3102695902 @default.
• W2560639583 cites W4294216483 @default.
• W2560639583 cites W618557273 @default.
• W2560639583 cites W63564536 @default.
• W2560639583 doi "https://doi.org/10.18632/oncotarget.13884" @default.
• W2560639583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5356876" @default.
• W2560639583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27965461" @default.
• W2560639583 hasPublicationYear "2016" @default.
• W2560639583 type Work @default.
• W2560639583 sameAs 2560639583 @default.
• W2560639583 citedByCount "8" @default.
• W2560639583 countsByYear W25606395832017 @default.
• W2560639583 countsByYear W25606395832019 @default.
• W2560639583 countsByYear W25606395832020 @default.

• next